The North America PARP Inhibitor Biomarkers Testing Product Market is experiencing significant growth, driven by the increasing adoption of precision oncology, rising prevalence of BRCA-mutated cancers, and expanding use of companion diagnostic testing. The region benefits from advanced molecular diagnostic infrastructure, strong reimbursement frameworks, and continuous...